D. Western Therapeutics Institute Inc
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract su… Read more
D. Western Therapeutics Institute Inc (6DW) - Total Assets
Latest total assets as of June 2025: €1.51 Billion EUR
Based on the latest financial reports, D. Western Therapeutics Institute Inc (6DW) holds total assets worth €1.51 Billion EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
D. Western Therapeutics Institute Inc - Total Assets Trend (2009–2024)
This chart illustrates how D. Western Therapeutics Institute Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
D. Western Therapeutics Institute Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
D. Western Therapeutics Institute Inc's total assets of €1.51 Billion consist of 88.4% current assets and 11.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 67.5% |
| Accounts Receivable | €125.02 Million | 7.5% |
| Inventory | €101.96 Million | 6.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €44.43 Million | 2.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how D. Western Therapeutics Institute Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: D. Western Therapeutics Institute Inc's current assets represent 88.4% of total assets in 2024, a decrease from 98.2% in 2009.
- Cash Position: Cash and equivalents constituted 67.5% of total assets in 2024, up from 47.6% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 7.5% of total assets.
D. Western Therapeutics Institute Inc Competitors by Total Assets
Key competitors of D. Western Therapeutics Institute Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
D. Western Therapeutics Institute Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - D. Western Therapeutics Institute Inc generates 0.28x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - D. Western Therapeutics Institute Inc is currently not profitable relative to its asset base.
D. Western Therapeutics Institute Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.65 | 19.32 | 9.69 |
| Quick Ratio | 11.71 | 18.24 | 9.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.23 Billion | € 1.75 Billion | € 1.39 Billion |
D. Western Therapeutics Institute Inc - Advanced Valuation Insights
This section examines the relationship between D. Western Therapeutics Institute Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.32 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -29.7% |
| Total Assets | €1.67 Billion |
| Market Capitalization | $22.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values D. Western Therapeutics Institute Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: D. Western Therapeutics Institute Inc's assets decreased by 29.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for D. Western Therapeutics Institute Inc (2009–2024)
The table below shows the annual total assets of D. Western Therapeutics Institute Inc from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €1.67 Billion | -29.66% |
| 2023-12-31 | €2.37 Billion | -19.72% |
| 2022-12-31 | €2.96 Billion | +20.04% |
| 2021-12-31 | €2.46 Billion | -10.04% |
| 2020-12-31 | €2.74 Billion | +38.17% |
| 2019-12-31 | €1.98 Billion | -4.46% |
| 2018-12-31 | €2.07 Billion | -27.93% |
| 2017-12-31 | €2.88 Billion | -1.21% |
| 2016-12-31 | €2.91 Billion | +36.11% |
| 2015-12-31 | €2.14 Billion | +115.97% |
| 2010-12-31 | €990.89 Million | -29.83% |
| 2009-12-31 | €1.41 Billion | -- |